Ali Asif
Insider CIK 1921163 · PTGX Chief Financial Officer
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| PTGX Protagonist Therapeutics, | M Exercise deriv | 2026-09-30 | 2026-10-02 | 5,312 | — | $0 | 25,235 | SEC↗ |
| PTGX Protagonist Therapeutics, | M Exercise deriv | 2026-09-30 | 2026-10-02 | 15,650 | — | $0 | 51,150 | SEC↗ |
| PTGX Protagonist Therapeutics, | M Exercise deriv | 2026-09-30 | 2026-10-02 | 28,438 | — | $0 | 49,562 | SEC↗ |
| PTGX Protagonist Therapeutics, | M Exercise deriv | 2026-09-30 | 2026-10-02 | 9,229 | — | $0 | 29,291 | SEC↗ |
| PTGX Protagonist Therapeutics, | S Sale | 2026-09-30 | 2026-10-02 | 46,034 | $141.78 | $6.53M | 59,003 | SEC↗ |
| PTGX Protagonist Therapeutics, | S Sale | 2026-09-30 | 2026-10-02 | 12,595 | $141.77 | $1.79M | 105,037 | SEC↗ |
| PTGX Protagonist Therapeutics, | M Exercise | 2026-09-30 | 2026-10-02 | 5,312 | $12.17 | $64.6K | 117,632 | SEC↗ |
| PTGX Protagonist Therapeutics, | M Exercise | 2026-09-30 | 2026-10-02 | 15,650 | $19.19 | $300.3K | 112,320 | SEC↗ |
| PTGX Protagonist Therapeutics, | M Exercise | 2026-09-30 | 2026-10-02 | 28,438 | $23.42 | $666.0K | 96,670 | SEC↗ |
| PTGX Protagonist Therapeutics, | M Exercise | 2026-09-30 | 2026-10-02 | 9,229 | $38.98 | $359.7K | 68,232 | SEC↗ |
| PTGX Protagonist Therapeutics, | S Sale | 2026-04-20 | 2026-04-21 | 1,750 | $105.47 | $184.6K | 59,003 | SEC↗ |
| PTGX Protagonist Therapeutics, | M Exercise deriv | 2026-03-26 | 2026-03-27 | 19,500 | — | $0 | 31,300 | SEC↗ |
| PTGX Protagonist Therapeutics, | M Exercise deriv | 2026-03-26 | 2026-03-27 | 5,265 | — | $0 | 13,282 | SEC↗ |
| PTGX Protagonist Therapeutics, | M Exercise | 2026-03-26 | 2026-03-27 | 19,500 | $19.19 | $374.2K | 80,253 | SEC↗ |
| PTGX Protagonist Therapeutics, | M Exercise | 2026-03-26 | 2026-03-27 | 5,265 | $12.17 | $64.1K | 85,518 | SEC↗ |
| PTGX Protagonist Therapeutics, | S Sale | 2026-03-26 | 2026-03-27 | 24,765 | $104.24 | $2.58M | 60,753 | SEC↗ |
| PTGX Protagonist Therapeutics, | M Exercise deriv | 2026-01-27 | 2026-01-27 | 12,000 | — | $0 | 18,547 | SEC↗ |
| PTGX Protagonist Therapeutics, | M Exercise deriv | 2026-01-27 | 2026-01-27 | 16,000 | — | $0 | 50,800 | SEC↗ |
| PTGX Protagonist Therapeutics, | S Sale | 2026-01-27 | 2026-01-27 | 18,203 | $83.14 | $1.51M | 60,320 | SEC↗ |
| PTGX Protagonist Therapeutics, | S Sale | 2026-01-27 | 2026-01-27 | 28,000 | $83.13 | $2.33M | 78,523 | SEC↗ |
| PTGX Protagonist Therapeutics, | M Exercise | 2026-01-27 | 2026-01-27 | 16,000 | $19.19 | $307.0K | 94,523 | SEC↗ |
| PTGX Protagonist Therapeutics, | M Exercise | 2026-01-27 | 2026-01-27 | 12,000 | $12.17 | $146.0K | 106,523 | SEC↗ |
| PTGX Protagonist Therapeutics, | S Sale | 2026-01-20 | 2026-01-21 | 8,588 | $82.48 | $708.3K | 78,077 | SEC↗ |
| PTGX Protagonist Therapeutics, | A Award deriv | 2026-01-02 | 2026-01-06 | 32,000 | — | $0 | 32,000 | SEC↗ |
| PTGX Protagonist Therapeutics, | A Award | 2026-01-02 | 2026-01-06 | 25,600 | — | $0 | 86,665 | SEC↗ |
| PTGX Protagonist Therapeutics, | S Sale | 2025-04-22 | 2025-04-23 | 1,756 | $46.00 | $80.8K | 61,065 | SEC↗ |
| PTGX Protagonist Therapeutics, | M Exercise deriv | 2025-03-12 | 2025-03-14 | 9,700 | — | $0 | 66,800 | SEC↗ |
| PTGX Protagonist Therapeutics, | M Exercise deriv | 2025-03-12 | 2025-03-14 | 15,203 | — | $0 | 30,547 | SEC↗ |
| PTGX Protagonist Therapeutics, | S Sale | 2025-03-12 | 2025-03-14 | 24,903 | $58.73 | $1.46M | 62,821 | SEC↗ |
| PTGX Protagonist Therapeutics, | M Exercise | 2025-03-12 | 2025-03-14 | 9,700 | $19.19 | $186.1K | 87,724 | SEC↗ |
| PTGX Protagonist Therapeutics, | M Exercise | 2025-03-12 | 2025-03-14 | 15,203 | $12.17 | $185.0K | 78,024 | SEC↗ |
| PTGX Protagonist Therapeutics, | S Sale | 2025-01-16 | 2025-01-17 | 1,317 | — | $0 | 65,422 | SEC↗ |
| PTGX Protagonist Therapeutics, | S Sale | 2025-01-16 | 2025-01-17 | 2,601 | — | $0 | 62,821 | SEC↗ |
| PTGX Protagonist Therapeutics, | A Award deriv | 2025-01-02 | 2025-01-06 | 38,520 | — | $0 | 38,520 | SEC↗ |
| PTGX Protagonist Therapeutics, | A Award | 2025-01-02 | 2025-01-06 | 31,779 | — | $0 | 66,739 | SEC↗ |
| PTGX Protagonist Therapeutics, | M Exercise deriv | 2024-09-11 | 2024-09-13 | 6,000 | — | $0 | 45,750 | SEC↗ |
| PTGX Protagonist Therapeutics, | M Exercise deriv | 2024-09-11 | 2024-09-13 | 6,000 | — | $0 | 76,500 | SEC↗ |
| PTGX Protagonist Therapeutics, | S Sale | 2024-09-11 | 2024-09-13 | 12,000 | $44.47 | $533.6K | 34,960 | SEC↗ |
| PTGX Protagonist Therapeutics, | S Sale | 2024-09-11 | 2024-09-13 | 2,203 | $44.59 | $98.2K | 34,960 | SEC↗ |
| PTGX Protagonist Therapeutics, | M Exercise | 2024-09-11 | 2024-09-13 | 6,000 | $19.19 | $115.1K | 40,960 | SEC↗ |
| PTGX Protagonist Therapeutics, | M Exercise | 2024-09-11 | 2024-09-13 | 6,000 | $12.17 | $73.0K | 46,960 | SEC↗ |
| PTGX Protagonist Therapeutics, | S Sale | 2024-04-18 | 2024-04-19 | 1,234 | $25.11 | $31.0K | 37,163 | SEC↗ |
| PTGX Protagonist Therapeutics, | M Exercise deriv | 2024-03-01 | 2024-03-01 | 12,000 | — | $0 | 51,750 | SEC↗ |
| PTGX Protagonist Therapeutics, | M Exercise | 2024-03-01 | 2024-03-01 | 12,000 | $12.17 | $146.0K | 52,645 | SEC↗ |
| PTGX Protagonist Therapeutics, | S Sale | 2024-03-01 | 2024-03-01 | 12,000 | $32.22 | $386.6K | 40,645 | SEC↗ |
| PTGX Protagonist Therapeutics, | S Sale | 2024-03-01 | 2024-03-01 | 2,248 | $32.33 | $72.7K | 38,397 | SEC↗ |
| PTGX Protagonist Therapeutics, | S Sale | 2024-02-29 | 2024-03-01 | 7,850 | $30.61 | $240.3K | 42,734 | SEC↗ |
| PTGX Protagonist Therapeutics, | S Sale | 2024-02-29 | 2024-03-01 | 2,089 | $31.00 | $64.8K | 40,645 | SEC↗ |
| PTGX Protagonist Therapeutics, | F Tax w/h | 2024-01-16 | 2024-01-18 | 1,452 | $24.63 | $35.8K | 50,584 | SEC↗ |
| PTGX Protagonist Therapeutics, | A Award deriv | 2024-01-02 | 2024-01-04 | 78,000 | — | $0 | 78,000 | SEC↗ |
| PTGX Protagonist Therapeutics, | A Award | 2024-01-02 | 2024-01-04 | 21,000 | — | $0 | 52,036 | SEC↗ |
| PTGX Protagonist Therapeutics, | F Tax w/h | 2023-05-31 | 2023-06-02 | 4,150 | $26.07 | $108.2K | 31,036 | SEC↗ |
| PTGX Protagonist Therapeutics, | A Award | 2023-05-31 | 2023-06-02 | 12,000 | — | $0 | 35,186 | SEC↗ |
| PTGX Protagonist Therapeutics, | F Tax w/h | 2023-04-18 | 2023-04-19 | 1,189 | $23.21 | $27.6K | 23,186 | SEC↗ |
| PTGX Protagonist Therapeutics, | A Award deriv | 2023-01-16 | 2023-01-18 | 63,750 | — | $0 | 63,750 | SEC↗ |
| PTGX Protagonist Therapeutics, | A Award | 2023-01-16 | 2023-01-18 | 10,625 | — | $0 | 24,375 | SEC↗ |
| PTGX Protagonist Therapeutics, | A Award deriv | 2022-04-18 | 2022-04-19 | 82,500 | — | $0 | 82,500 | SEC↗ |
| PTGX Protagonist Therapeutics, | A Award | 2022-04-18 | 2022-04-19 | 13,750 | — | $0 | 13,750 | SEC↗ |